<DOC>
	<DOCNO>NCT01156909</DOCNO>
	<brief_summary>Based pilot patient observation , experience prior study KTS-1-2008 , investigator anticipate chronic fatigue syndrome patient may benefit B-cell depletion therapy use Rituximab induction maintenance treatment . The hypothesis least subset CFS patient activate immune system involve B-lymphocytes , prolong B-cell depletion may alleviate symptom .</brief_summary>
	<brief_title>B-cell Depletion Using Monoclonal Anti-CD20 Antibody Rituximab Chronic Fatigue Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Encephalomyelitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>patient CFS age 1866 year informed consent patient fatigue , fulfil criterion CFS pregnancy lactation previous malignant disease except basal cell carcinoma skin cervical carcinoma situ previous major immunological disease , except autoimmune disease diabetes mellitus thyroiditis previous longterm use immunosuppressive drug , except steroid e.g . obstructive lunge disease endogenous depression lack ability comply protocol multiallergy risk serious drug reaction reduce renal function ( creatinin &gt; 1.5 x UNL ) reduce liver function ( bilirubin transaminase &gt; 1.5 x UNL ) HIV positivity evidence clinically significant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic fatigue syndrome</keyword>
	<keyword>CFS</keyword>
	<keyword>Myalgic encephalomyelitis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-cell depletion</keyword>
</DOC>